SRI international:1110101 [20-008697]
Ended Awarded Last action
- Contract number
- 75N95020F00002
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $130,912
Award facts
- Contract value 31% obligated
-
- $130,912.05 Current, with exercised options
- $419,472.05 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$6,901 | |
| Original award | $137,813 |
About this award
Sri International, a non-profit research and development organization headquartered in Menlo Park, California, was awarded a parent Indefinite Delivery Indefinite Quantity (IDIQ) contract by the National Institute on Drug Abuse (NIDA) under the Pharmacology and Toxicology for Therapeutics Program (PTTP). This delivery order contract, valued at approximately $419K with a cost-plus-fixed-fee pricing structure, was awarded on September 15, 2020, with an ultimate completion date of September 17, 2021. The contract does not carry a small business set-aside designation. Work will be performed at Sri International's facility in Menlo Park, California.
As the parent IDIQ vehicle for the PTTP, this contract establishes the framework through which NIDA can issue task orders for pharmacology and toxicology research services supporting the agency's therapeutic development initiatives. Sri International's multidisciplinary research capabilities position it to support NIDA's mission of advancing drug abuse prevention and treatment through scientific investigation. The IDIQ structure provides NIDA with flexible access to Sri International's specialized expertise in safety evaluation and toxicology studies, enabling rapid procurement of research services across multiple scientific investigations related to drug therapeutics and related pharmacological research.
Quick answers
Who was awarded contract 75N95020F00002?
75N95020F00002 was awarded to Sri International by National Institute on Drug Abuse (National Institutes of Health) on September 15, 2020.
How much is contract 75N95020F00002 worth?
The government has obligated $130,912 on 75N95020F00002. Its potential value, with all options, is $419,472.
Is contract 75N95020F00002 an order under another contract?
Yes. 75N95020F00002 is a delivery order under HHSN271201600006I, an indefinite delivery contract, on Pharmacology and Toxicology for Therapeutics Program (PTTP).
Was contract 75N95020F00002 competed?
The extent of competition for 75N95020F00002 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award